Metabolic reprogramming of myeloid‑derived suppressor cells in colorectal cancer: Mechanistic insights and immunometabolic targeted rehabilitation (Review)

Authors:

Abstract
Metabolic reprogramming of myeloid‑derived suppressor cells (MDSCs) plays a role in immunotherapy resistance in colorectal cancer (CRC). This metabolic reprogramming appears to be coordinated by oncogenic mutations (such as adenomatous polyposis coli, KRAS and TP53) through a proposed self‑reinforcing ‘mutation‑metabolism‑suppression’ axis. In the present review, four core metabolic pillars sustaining MDSC pathogenicity and the epimetabolic regulation that durably locks them into a suppressive state were examined. Furthermore, two emerging dimensions were highlighted: The spatial metabolic antagonism through which MDSCs may construct a metabolically hostile zone to limit the functional activity of tertiary lymphoid structures, and the remote manipulation of MDSC function by gut and intratumoral microbiota‑derived metabolites. To transcend the limitations of non‑specific myeloid depletion, immunometabolic rehabilitation is proposed as a potentially transformative framework targeting intrinsic metabolic vulnerabilities to functionally reprogram MDSCs from an immunosuppressive to a homeostatic or immunostimulatory phenotype. By integrating emerging spatial omics for precise target validation, artificial intelligence‑guided rational drug design and microbiome modulation, this paradigm provides a strategic roadmap for next‑generation precision immunotherapy, aiming to achieve durable responses across both microsatellite stable and microsatellite instability‑high CRC.

This publication has 125 references indexed in Scilit: